Dr. Amanda Waddle returns to Health Centered Dentistry to provide care to all. ANCHORAGE, ALASKA, UNITED STATES, September 1, 2022 /EINPresswire.com/ — Health Centered Dentistry is excited to welcome Amanda Waddle, DDS, to its team. Dr. Amanda Waddle was born and raised in Anchorage, Alaska, and is a distinguished dental provider who brings a radiant, […]
Day: September 6, 2022
Mudda Aapka: One Nation one Health | 30 May, 2022
संसद टीवी के ख़ास कार्यक्रम मुद्दा आपका में आज बात करेंगे एक देश एक स्वास्थ्य प्रणाली की। हाल ही में राष्ट्रपति राम नाथ कोविंद जी ने एक कार्यक्रम में इस बात पर जोर दिया कि देश का हर व्यक्ति, प्रत्येक परिवार, हर गांव और शहर स्वस्थ होगा तो पूरा देश स्वस्थ होगा। वर्ष 2017 में […]
Kerr Dental’s Nexus™ RMGI Offers Smart Response Ion Technology to Help Prevent Secondary Caries
Featuring the Smart Response Ion Technology, Nexus™ RMGI has been proven to offer a sustained ion release that helps prevent secondary caries.
BREA, Calif. – September 6, 2022 – (Newswire.com)
Kerr Dental announces the relaunch of Nexus RMGI, a resin-modified glass ionomer luting cement featuring Smart Response Ion Technology. The first RMGI available with advanced NexusTM Technology, Nexus RMGI is formulated for easy cleanup, outstanding bond strength, great color stability, and provides sustained ion release to help prevent secondary caries.
Since its original launch in 2013, NexusTM RMGI has been known for its proprietary One-Peel™ Cleanup that simplifies cleanup during the luting process – making it the cement of choice for many dental professionals. Kerr Dental customers will be pleased to learn that in addition to being easier to use, recent studies have shown that the NexusTM RMGI also offers sustained ion release that can help prevent secondary caries.
Featuring Kerr’s Smart Response Ion Technology, the NexusTM RMGI is formulated for a sustained release of fluoride, as well as calcium and zinc in acidic environments, thus providing antibacterial properties to help prevent secondary caries.
Lea Pagaduan, Senior Marketing Manager at Kerr Dental, says, “Doctors want to have confidence that an RMGI will continue to perform well after restoration placement. The Smart Response Ion Technology gives doctors that confidence, making Nexus RMGI the cement of choice to help protect against secondary caries.”
Pagaduan continued, “NexusTM RMGI also features easy clean-up and a dual-adhesive system that provides 50-80% greater bond strength relative to other leading brands for metal and zirconia crowns.”
Features like Smart Response Ion Technology, One-Peel Cleanup, and the highest bond strength combined in Nexus RMGI provide doctors with a luting cement that helps them work faster and with greater confidence in the outcomes.
To learn more about Nexus RMGI’s One-Peel Cleanup, outstanding bond strength, and Smart Response Ion Technology, visit kerrdental.com.
For Further Information
Kerr Dental
200 S. Kraemer Blvd., Building E
Brea, CA 92821
Telephone: (949) 294-6251
Press Release Service
by
Newswire.com
Original Source:
Kerr Dental’s Nexus™ RMGI Offers Smart Response Ion Technology to Help Prevent Secondary Caries
Felsen Joins AAPPR’s Diversity, Equity, & Inclusion Advisory Committee
Health eCareers partners with industry professionals for DE&I
DENVER – September 6, 2022 – (Newswire.com)
Health eCareers announced today that account executive Li Felsen has joined the Association for Advancing Physician and Provider Recruitment‘s Diversity, Equity, & Inclusion Advisory Committee.
The committee was created in 2021 to ensure inclusiveness for physician and provider recruitment professionals. Comprised of both association members and strategic partners, the committee reviews policies, structures, relationships, and opportunities to advance DEI.
“It is an honor to be a part of AAPPR’s DEI Advisory committee,” said Felsen. “Having the opportunity to serve our industry and those who serve others is both a passion and a mission for me.”
Felsen has managed major and strategic accounts in the Northeast, Southeast, Texas, and the West Coast since 2013. Her clients comprise some of the top health systems and staffing firms across the country including Dignity Health, Kaiser Permanente, Providence Health, PeaceHealth, and CHG. In addition to her passion for elevating attention for DEI initiatives, Felsen also is the co-founder and co-president of Ziff Davis’ LatinX employee resource group and is a member of its DEI Council. She is also a two-time winner of the company’s Leadership Achievement Award.
“Li’s passion for her clients, our industry, and her coworkers is shown in everything she does,” said Greg Chang, managing director at Health eCareers. “Like Li, Health eCareers is committed to serving the healthcare recruitment industry and healthcare professionals and believe diversity, equity, and inclusion must continually be raised to the forefront,” added Chang.
“The addition of Li Felsen to the DEI Advisory Committee adds a valuable new perspective to our work to educate and equip our AAPPR members,” said Carey Goryl, CEO of AAPPR. “In her position, Li will help form our own approach to DEI, guide membership discussions surrounding DEI and develop valuable educational resources like our Diversity Recruitment Micro Certification to help physician and provider recruiters enhance their recruitment strategies in support of systematic change.”
As part of Health eCareers’ continued focus around DEI initiatives it will be co-hosting a free webinar with CHG and physician recruitment industry leaders from Emory Healthcare, ChenMed, and the Veterans Health Administration on Sept. 13 at 2 p.m. EST. The webinar will include speakers from AAPPR’s DEI Advisory Committee and attendees are eligible to earn up to one continuing education credit from the association.
###
About Health eCareers
Health eCareers is the leading healthcare recruitment network serving professionals, employers, and partners. To learn more, visit healthecareers.com, or find them on Facebook and Twitter. Health eCareers is part of the Everyday Health Group.
About The Association for Advancing Physician and Provider Recruitment
The Association for Advancing Physician and Provider Recruitment (AAPPR) is a nationally recognized leader in health care provider recruitment, onboarding, and retention. For more than 30 years, AAPPR has empowered physician and advanced practice provider recruitment leaders to transform care delivery in their communities by providing best-in-class practices, up-to-date industry knowledge, and evolving innovative approaches for hiring, onboarding, and retaining exceptional clinical talent. To learn more, please visit https://aappr.org.
###
Media Contact
Christine Burke, Marketing Director
[email protected]
Press Release Service
by
Newswire.com
Original Source:
Felsen Joins AAPPR’s Diversity, Equity, & Inclusion Advisory Committee
Apprentice Introduces Augmented Work Instructions (AWI) to Help Life Science Organizations Kickstart Their Digital Transformation
For manufacturers to take the first step from paper to digital
JERSEY CITY, N.J. – September 6, 20…
TODAY: Gb Sciences Describes Drug Development Progress in Pharma’s Almanac Journal Article
Gb Sciences is focusing considerable resources on bringing its lead Parkinson’s disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.
LAS VEGAS – September 6, 2022 – (Newswire.com)
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, describes their progress towards achieving significant milestones in their drug development pipeline in an article published in the journal Pharma’s Almanac today at https://www.pharmasalmanac.com/articles/unlocking-the-therapeutic-potential-of-plant-inspired-minimum-essential-mixtures.
“Gb Sciences is focusing considerable resources on bringing our lead Parkinson’s disease formulations to the clinic with promising results already obtained during the formulation of Oral Dissolving Tablets containing our active ingredients for use in human clinical trials,” said Dr. Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences. “We have new data validating the efficacy of our novel anxiety formulations in an animal model, as well as new data demonstrating the improved stability of our oral nanoparticle-encapsulated chronic pain formulations based on newly-adopted manufacturing control processes.”
The full article entitled “Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures” also provides some context for their recent drug development successes by discussing Gb Sciences’ evolution from a cannabis company to a plant-inspired biopharmaceutical company and what makes their drug development approach truly unique. With conventional drug discovery efforts failing to deliver on some critical medical needs, such as non-opioid treatments for chronic pain, there may be value in exploring plants associated with traditional medicines to discover new drug molecules and simplified mixtures. Gb Sciences is connecting plant-based medicine with modern in silico drug discovery tools, leveraging a unique AI-enabled platform to mine plant species and compounds to uncover minimum essential mixtures of molecules with therapeutic benefits and reduced side effect profiles.
To learn more about Gb Sciences, visit www.gbsciences.com.
About Gb Sciences and GbS Global Biopharma
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome related to COVID-19, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Media Contact
Alexis Quintal
[email protected]
Press Release Service
by
Newswire.com
Original Source:
TODAY: Gb Sciences Describes Drug Development Progress in Pharma’s Almanac Journal Article
The FACELIFT Makeup | Best Tips for Older Women, Over 50 | Dominique Sachse
Here’s how you can get an instant facelift using makeup and creativity! These makeup application tips are great for women over 50 who want to look younger than their age. Here’s my in-depth makeup application tutorial that takes you step by step and shows you what to do and what not to do! Facelift makeup […] …
April 2022 Clean Beauty News
In this video, I provide updates on the latest brands, products, releases from Beauty Heroes, Credo, and Detox Market from April 2022!
Instagram: NaturalBeautywithMelanie
Originally published at https://www.youtube.com/watch?v=uEEWwZQp0WE